Upstream Bio says Phase 2 trial shows verekitug improves asthma control in CRSwNP patients

UpStream Bio

UpStream Bio

UPB

0.00
  • Upstream Bio presented new Phase 2 VIBRANT trial data at the ATS 2026 International Conference on verekitug in adults with chronic rhinosinusitis with nasal polyps, including patients with comorbid asthma.
  • The analyses showed improved asthma symptom control in patients with comorbid asthma, alongside consistent reductions in nasal polyp burden and sinonasal symptoms versus placebo.
  • Verekitug also lowered the need for rescue systemic steroids or sinus surgery in the comorbid asthma subgroup.
  • A separate post hoc analysis indicated rapid, sustained reductions in type 2 inflammatory biomarkers in blood and nasal secretions, supporting the drug’s proposed mechanism in airway inflammation.
  • Upstream Bio expects to start dosing Phase 3 registrational trials in CRSwNP and severe asthma in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181130PRIMZONEFULLFEED9722168) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.